

INNOVASSYNTH INVESTMENTS LIMITED							
CIN : L67120MH2008PLC178923							
Regd. Office: Flat No. C-2/3, KMC No.91, Innovassynth Colony, Khopoli - 410203, Maharashtra							
Website: www.innovassynthinvestments.in   E-mail: secretarial@innovassynthinvestments.in							
EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE, 2023							
(₹ in Lakhs)							
Sr. No.	Particulars	STANDALONE			CONSOLIDATED		
		Quarter ended 30 June, 2023	Quarter ended 31 March, 2023	Quarter ended 30 June, 2022	Quarter ended 30 June, 2023	Quarter ended 31 March, 2023	Quarter ended 30 June, 2022
1	Total Income from Operations	-	-	1.96	-	-	1.96
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(18.27)	(16.08)	(15.95)	(18.27)	(16.08)	(15.95)
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(18.27)	(16.08)	(15.95)	(18.27)	(16.08)	(15.95)
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(18.27)	(16.08)	(15.95)	(18.27)	(16.08)	(15.95)
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(18.27)	(16.08)	(15.95)	(506.56)	575.93	(24.30)
6	Equity Share Capital	2,427.80	2,427.80	2,427.80	2,427.80	2,427.80	2,427.80
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year*#	-	-	-	-	-	-
8	Earnings Per Share (of ₹ 10/- each)** (for continuing and discontinued operations) -						
	1. Basic:	(0.08)	(0.07)	(0.07)	(2.09)	1.74	(0.10)
	2. Diluted:	(0.08)	(0.07)	(0.07)	(2.09)	1.74	(0.10)

The standalone and consolidated unaudited financial results of the company for the quarter ended 30 June 2023 have been reviewed by Audit Committee at their meeting held on 11 August 2023 and approved by the Board of Directors in its meeting held on 11 August 2023. The Statutory Auditors of the Company have reviewed above results for quarter ended 30 June 2023.

**Note** :- The above is an extract of the detailed format of quarter ended financial results for 30 June 2023 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of the quarterly financial results are available on the Stock Exchanges Website- www.bseindia.com and on the company's website- www.innovassynthinvestments.in.

For and on behalf of the Board of Directors of Innovassynth Investments Limited

Dr. Hardik Joshipura CMD  
Samer Pakhali CS and CFO  
DIN: 09392511

Place: Khopoli  
Date: 11th August, 2023

VIDHI SPECIALTY FOOD INGREDIENTS LIMITED								
[CIN: L24110MH1994PLC076156]								
Registered Office: E/27, Commerce Center 78, Tardeo Road, Mumbai-400034								
Phone No.: 022-6140 6666; Fax No.: 022-23521980								
Email: mitesh.maneke@vidhifoodcolors.com Website: https://vidhifoodcolors.com/								
Extract of Un-audited Financial Results for the first Quarter ended June 30, 2023								
(Rupees in Lakhs)								
Particulars	Standalone				Consolidated			
	Quarter Ended June 30, 2023 (Un-Audited)	Quarter Ended March 31, 2023 (Audited)	Quarter Ended June 30, 2022 (Un-Audited)	Financial Year ended March 31, 2023 (Audited)	Quarter Ended June 30, 2023 (Un-Audited)	Quarter Ended March 31, 2023 (Audited)	Quarter Ended June 30, 2022 (Un-Audited)	Financial Year ended March 31, 2023 (Audited)
Total Income from operations	8,028.40	9,007.27	12,107.01	40,520.28	8,028.40	9,007.27	12,107.01	40,520.28
Net Profit for the period (before tax, Exceptional and/or Extraordinary items)	1,154.84	1,111.35	1,480.66	4,995.45	1,153.90	1,103.51	1,481.66	4,979.95
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	1,154.84	1,111.35	1,480.66	4,995.45	1,153.90	1,103.51	1,481.66	4,979.95
Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	837.58	886.23	1,100.24	3,785.50	836.64	878.39	1,101.24	3,770.00
Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and other Comprehensive Income (after Tax)]	838.65	880.46	1,101.78	3,788.75	837.71	873.91	1,102.78	3,773.25
Equity share capital (Face Value of Equity Share Rs. 1/- Per Share)	499.45	499.45	499.45	499.45	499.45	499.45	499.45	499.45
Other Equity	-	-	-	24639.25	-	-	-	24572.69
Earnings Per Share (of Rs. 1/- each) (for continuing operations)								
Basic:	1.68	1.76	2.21	7.59	1.68	1.75	2.21	7.55
Diluted:	1.68	1.76	2.21	7.59	1.68	1.75	2.21	7.55

**Note** :-

- The results for the quarter ended June 30, 2023 were reviewed by the Audit Committee and approved by the Board of Directors in its meeting held on August 11, 2023. The Statutory Auditors of the Company has carried out a Limited Review of the aforesaid results in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Company operates in single business segment namely manufacturing and trading of food colors and chemicals. Hence, no separate disclosure as per "Ind AS-108" is required for the Operating segment.
- The figures for the quarter ended March 31, 2023 are the balancing figures between the audited figures in respect of the full financial year ended on March 31, 2023 (Ind AS) and the published year to date Ind AS figures upto the third quarter ended on December 31, 2022, which were subjected to a limited review.
- Previous period's figures have been regrouped / reclassified, wherever necessary to make them comparable with the current period / year.

For Vidhi Specialty Food Ingredients Limited  
Sd/-  
Bipin M. Maneke  
Chairman & Managing Director  
DIN: 00416441

Place: Mumbai  
Date: August 11, 2023

MARKSANS PHARMA LIMITED							
CIN: L24110MH1992PLC066364							
Registered Office: 11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (West), Mumbai - 400053. Telephone No.: 022-4001 2000, Fax No.: 022-4001 2011, E-mail: companysecretary@marksanspharma.com							
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2023							
(₹ in million except per equity share data)							
Sr. No.	PARTICULARS	STANDALONE			CONSOLIDATED		
		QUARTER ENDED		Year ended	QUARTER ENDED		Year ended
		30.06.2023 (UNAUDITED)	30.06.2022 (UNAUDITED)	31.03.2023 (AUDITED)	30.06.2023 (UNAUDITED)	30.06.2022 (UNAUDITED)	31.03.2023 (AUDITED)
1	Total Income from operations	2,146.64	1,785.84	7,156.86	5,101.29	4,502.67	19,114.52
2	Net Profit/(Loss) for the period before Tax	543.95	257.04	1,320.35	968.26	764.45	3,376.53
3	Net Profit/(Loss) for the period after Tax	441.91	192.06	1,028.66	704.38	601.84	2,653.21
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	440.29	192.17	1,022.75	872.30	679.62	3,175.32
5	Paid up Equity Share Capital (face value ₹1 each fully paid)	453.16	409.31	453.16	453.16	409.31	453.16
6	Earnings per equity share of ₹1 each*						
	-Basic	0.98	0.47	2.48	1.52	1.46	6.41
	-Diluted	0.98	0.47	2.48	1.52	1.46	6.41

\* EPS is not annualised for the quarter ended 30 June 2023, 31 March 2023 and 30 June 2022.

**Note**: The above is an extract of the detailed format of Unaudited Financial Results for the Quarter ended 30 June 2023 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of Unaudited Financial Results are available on www.nseindia.com and www.bseindia.com and Company's website www.marksanspharma.com.

For MARKSANS PHARMA LIMITED  
Sd/-  
MARK SALDANHA  
Chairman & Managing Director  
DIN : 00020983

Place : Mumbai  
Date : 11th August, 2023  
www.marksanspharma.com

The shareholders who have not registered their e-mail addresses are requested to register them with the Company to receive e-communication from the Company. For registering e-mail address, the shareholders are requested to follow the below steps:  
i. Shareholders holding shares in physical mode are requested to provide name, folio number, mobile number, e-mail address, scanned copies of self attested share certificate(s) (both sides) copy of PAN/ Aadhaar through e-mail on companysecretary@marksanspharma.com or alternatively, do the same through the Registrar and Transfer Agent's website link at: https://www.bigshareonline.com/InvestorRegistration.aspx.  
ii. Shareholders holding shares in dematerialised mode are requested to register their email addresses and mobile numbers with their relevant depositories through their depository participants.

KLG CAPITAL SERVICES LIMITED									
Regd. Office : SKIL House, 209, Bank Street Cross Lane, Fort, Mumbai - 400 023. CIN : L67120MH1994PLC218169									
E-mail: company.secretary@klgcapital.com, Website: www.klgcapital.com, Tel. No.: +91-22-66199000, Fax No.: +91-22-22696024									
Unaudited Financial Results for The Quarter ended 30th June, 2023									
(Rs in Lacs except otherwise stated)									
Sr. No.	Particulars	Standalone				Consolidated			
		Quarter ended 30/06/2023 (Unaudited)	Quarter ended 31/03/2023 (Audited)	Quarter ended 30/06/2022 (Unaudited)	Year ended 31/03/2023 (Audited)	Quarter ended 30/06/2023 (Unaudited)	Quarter ended 31/03/2023 (Audited)	Quarter ended 30/06/2022 (Unaudited)	Year ended 31/03/2023 (Audited)
1	Total Income from operations (net)	19.30	27.47	19.15	84.49	19.30	27.47	19.15	84.49
2	Net Profit / (Loss) for the Period (Before Tax, Exceptional and/or Extraordinary Items)	(2.37)	4.72	2.14	(6.17)	(2.37)	4.27	2.14	(6.63)
3	Net Profit / (Loss) for the Period Before Tax (After Exceptional and/or Extraordinary Items)	(2.37)	4.72	2.14	(6.17)	(2.37)	4.27	2.14	(6.63)
4	Net Profit / (Loss) for the Period After Tax (After Exceptional and/or Extraordinary Items)	(2.38)	4.67	1.59	(6.22)	(2.38)	4.22	1.59	(6.68)
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the Period (After Tax) and Other Comprehensive Income (After Tax))	NA	NA	NA	NA	NA	NA	NA	NA
6	Equity Share Capital	320.24	320.24	320.24	320.24	320.24	320.24	320.24	320.24
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year).	-	-	-	435.69	-	-	-	428.74
8	Earnings Per Share (of Rs. 10/- each) for Continuing and discontinued operations								
	Basic :	(0.07)	0.15	0.05	(0.19)	(0.07)	0.13	0.05	(0.21)
	Diluted:	(0.07)	0.15	0.05	(0.19)	(0.07)	0.13	0.05	(0.21)

**NOTES** :-

- The above is an extract of the detailed format of Annual / Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Annual Financial Results are available on the Company's website at www.klgcapital.com and the website of Stock Exchanges where the Equity Shares of the Company are listed i.e. BSE Limited at www.bseindia.com.
- The above Standalone and Consolidated Financial Results were reviewed by Audit Committee and thereafter approved by the Board of Directors in their respective Meeting held on 11-08-2023.
- The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards (Ind-AS) notified under the Companies (Indian Accounting Standards) (Amendment) Rules, 2016, as amended and as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules there under and other accounting principles generally accepted in India.
- The figures for the quarter ended March 31, 2023 as reported in these financial results are balancing figures between the audited figures in respect of the Financial Year and restated year to date figures upto the end of the third quarter of the Financial Year.
- The figures for the previous corresponding periods have been regrouped/rearranged, wherever necessary, to make them comparable.

By order of the Board of Directors  
For KLG Capital Services Limited  
Sd/-  
CHINTAN RAJESH CHHEDA  
Director - DIN : 08098371

Place: Mumbai  
Date : August 11, 2023

ASHAPURA MINECHEM LIMITED									
Registered Office: Jeevan Udyog Building, 3rd Floor, 278, D. N. Road, Fort, Mumbai - 400 001.									
Tel. No.: +91-22 66221700 Fax: +91-22 22074452 Website: www.ashapura.com									
Investor Relations E-mail-ID: cosec@ashapura.com CIN: L14108MH1982PLC026396									
STATEMENT OF STANDALONE / CONSOLIDATED UNAUDITED FINANCIAL RESULTS									
FOR THE QUARTER ENDED 30th JUNE, 2023									
(₹ in Lacs)									
PARTICULARS	Standalone				Consolidated				Year Ended 31-03-2023 (Audited)
	Quarter Ended		Year Ended		Quarter Ended		Year Ended		
	30-06-2023 (Unaudited)	31-03-2023 (Audited * Refer Note 6)	30-06-2022 (Unaudited)	31-03-2023 (Audited)	30-06-2023 (Unaudited)	31-03-2023 (Audited * Refer Note 6)		30-06-2022 (Unaudited)	
1. <b>Income</b>									
(a) Income from Operations	9,072.81	4,669.24	6,840.30	22,269.17	1,01,796.01	69,620.02	40,183.20	1,83,084.84	
(b) Other Income	316.58	1,024.34	551.77	4,001.41	3,219.88	2,187.47	1,644.53	8,612.37	
<b>Total Income</b>	<b>9,389.38</b>	<b>5,693.58</b>	<b>7,392.06</b>	<b>26,270.58</b>	<b>1,05,015.89</b>	<b>71,807.49</b>	<b>41,827.73</b>	<b>1,91,697.21</b>	
2. <b>Expenses</b>									
(a) Cost of materials consumed	1,957.95	1,614.88	1,303.02	5,951.68	13,959.09	21,119.13	9,736.01	47,223.58	
(b) Purchase of Stock-in-trade	553.99	(906.07)	1,477.48	1,699.74	7,788.65	3,925.08	3,184.08	12,982.86	
(c) Changes in inventories	(171.52)	615.10	341.98	852.28	6,161.09	(3,145.74)	(3,077.15)	(10,855.51)	
(d) Employee benefits expenses	821.58	561.81	669.22	2,933.15	2,786.83	2,542.76	2,522.38	10,617.90	
(e) Finance costs	445.07	452.08	652.41	2,239.39	1,950.07	1,926.52	1,297.39	6,431.78	
(f) Depreciation & amortisation expenses	255.78	254.30	465.88	1,538.34	1,826.63	1,937.33	1,650.58	7,256.36	
(g) Selling & Distribution expenses	526.74	925.52	1,747.42	5,559.61	52,280.74	29,114.24	14,261.45	69,856.45	
(h) Other expenses	1,462.82	1,299.67	1,655.25	6,078.72	7,874.28	10,157.36	8,462.31	36,003.17	
<b>Total Expenses</b>	<b>5,852.40</b>	<b>4,817.27</b>	<b>8,312.66</b>	<b>26,852.93</b>	<b>94,619.37</b>	<b>67,576.67</b>	<b>38,037.05</b>	<b>1,79,516.60</b>	
3. <b>Profit / (Loss) before exceptional items &amp; tax (1-2)</b>	<b>3,536.98</b>	<b>876.31</b>	<b>(920.60)</b>	<b>(582.34)</b>	<b>10,396.52</b>	<b>4,230.82</b>	<b>3,790.68</b>	<b>12,180.61</b>	
4. Exceptional Items Gain / (Loss) (Refer Note 3)	36.73	-	-	-	(129.75)	-	-	-	
5. <b>Profit / (Loss) before tax (3+4)</b>	<b>3,573.72</b>	<b>876.31</b>	<b>(920.60)</b>	<b>(582.34)</b>	<b>10,266.77</b>	<b>4,230.82</b>	<b>3,790.68</b>	<b>12,180.61</b>	
6. Tax Expenses									
(a) Current Tax	-	-	-	-	1,262.87	1,157.57	477.63	2,385.53	
(b) Earlier years' tax	-	118.77	-	118.77	-	117.40	-	578.02	
(c) Deferred Tax	(652.32)	-	-	-	(644.74)	(119.01)	219.07	9.32	
7. <b>Profit / (Loss) for the period (5-6)</b>	<b>4,226.04</b>	<b>757.54</b>	<b>(920.60)</b>	<b>(701.12)</b>	<b>9,648.64</b>	<b>3,074.85</b>	<b>3,093.98</b>	<b>9,207.74</b>	
8. Share of Profit / (Loss) of joint ventures & associates (net)	-	-	-	-	549.04	903.69	422.47	1,765.61	
9. <b>Profit / (Loss) for the period (7+8)</b>	<b>4,226.04</b>	<b>757.54</b>	<b>(920.60)</b>	<b>(701.12)</b>	<b>10,197.68</b>	<b>3,978.54</b>	<b>3,516.45</b>	<b>10,973.35</b>	
10. Other Comprehensive Income / (Loss)									
<b>A Items that will not be reclassified to profit or loss</b>									
(i) Remeasurements of defined benefit plans (net of tax)	(1.93)	49.02	(18.91)	(7.70)	(8.11)	25.62	(19.25)	(32.39)	
(ii) Gains on Investments in equity instruments classified as FVOCI	-	-	-	-	-	-	-	-	
<b>B Items that will be reclassified to profit or loss</b>									
(i) Exchange differences on foreign currency translation	-	-	-	-	(826.84)	2,201.23	469.11	2,281.12	
<b>Total Other Comprehensive income (net of tax)</b>	<b>(1.93)</b>	<b>49.02</b>	<b>(18.91)</b>	<b>(7.70)</b>	<b>(834.95)</b>	<b>2,226.85</b>	<b>448.86</b>	<b>2,248.73</b>	
11. <b>Total Comprehensive income for the period (net of tax)</b>	<b>4,224.11</b>	<b>806.56</b>	<b>(939.51)</b>	<b>(708.82)</b>	<b>9,362.73</b>	<b>6,205.39</b>	<b>3,966.32</b>	<b>13,222.08</b>	
12. <b>Profit for the period attributable to:</b>									
(a) Shareholders of the Company	-	-	-	-	10,280.59	3,995.68	3,920.53	11,700.64	
(b) Non-controlling interests	-	-	-	-	(82.90)	(17.14)	(404.08)	(727.29)	
<b>Total Comprehensive income for the period attributable to:</b>									